MARKET WIRETradingView • 6h ago
Journey Medical Corporation Estimates – NASDAQ:DERMTradingView report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
Why DERM Stock dropped -4.44% Today — RQD Quant Desk Flash
$5.17 -4.44% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $5.12
Journey Medical Corporation (DERM) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $152.7M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on DERM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is DERM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Journey Medical Corporation (NASDAQ: DERM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $5.17 (-4.44% 1D, market cap $152.7M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DERM ranks #810 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does DERM compare to ALXO and MGNX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DERM carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 65.8%, and ROIC of -19.5%. By comparison, ALXO (ALX Oncology Holdings Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $152.4M) and MGNX (MacroGenics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $151.6M). Among the 5-stock peer group, DERM leads on earnings multiple (N/A) while DERM leads on capital efficiency (-19.5% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for DERM?
▼
Per DERM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001867066), Journey Medical Corporation generated $61.2M in revenue (+11.1% YoY), -$11.4M in net income, and -$12.4M in free cash flow against $94.6M in total assets and $25.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $5.12 (-0.99%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-12.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DERM)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY DERM SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (39% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (32% of score)
FRED Regime × Technicals: 16% of 52W Range • RSI-14 at 40.5 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$6.31-21.2% Next Q
39
Q2 (-2Q)Grade E$4.97+1% Next Q
36
Q3 (-1Q)Grade E$5.02+3% Next Q
34
CurrentGrade E$5.17-9.4% Hist 90D α
31
Trajectory: E (39) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a DERM Turnaround Squeeze
While DERM currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.52) and Max Pain ($5.43) forces dealer call-delta covering toward $10.04.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $DERM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “DERM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why DERM Stock dropped -4.44% Today — RQD Quant Desk Flash
Journey Medical Corporation (DERM) dropped -4.44% to $5.17, trading at 16% of its 52-week range ($4.31 – $9.56). Stretched risk/reward at current multiples (-20% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 16% of its 52-week range ($4.31 – $9.56) with RSI-14 at 40.5 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $5.17 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 65.8% gross margin and $0 annual free cash flow.
Live DERM Headlines & Catalysts
MARKET WIREStock Titan • 9h ago
An investment adviser reports passive ownership of 2.45M shares in Journey Medical (DERM).Stock Titan report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 12h ago
Journey Medical (NASDAQ:DERM) Stock Moved Down to "Hold" by Wall Street ZenMarketBeat report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 15h ago
Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains?Yahoo Finance report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
CATALYSThttps://www.siam.in/ • 18h ago
Journey Medical Corporation (DERM) Jumps 6.04% as Shares Reclaim Ground Toward $5.09 - Fair Value Gaphttps://www.siam.in/ report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 21h ago
Journey Medical's (DERM) Buy Rating Reiterated at HC WainwrightMarketBeat report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 1d ago
Medexus Pharmaceuticals Inc. (MDP.TO) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
Journey Medical Q3 2026 Earnings Date and EstimatesMarketBeat report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 7d ago
HC Wainwright & Co. Reiterates Buy on Journey Medical, Maintains $13 Price TargetHC Wainwright & Co. analyst Brandon Folkes reiterates Journey Medical (NASDAQ:DERM) with a Buy and maintains $13 price target.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DERM)
- ✓Walkthrough of DERM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
DERM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +0.39%📐 HORIZONTAL RANGE
2026-10-30O $5.37H $5.37L $5.10C $5.17VOL 235.0K
RES: $9.10SUP: $4.58SMA50: $6.52SMA200: $6.64
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
DERM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +11.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on DERM today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for DERM. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for DERM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DERM)
Health Care Rank #810 of 1016
⚔️ ALXO vs DERM Full Matrix →
1. Head-to-Head Health Care Peer Comparison (DERM vs. ALXO, MGNX, NGEN, CUE)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Journey Medical Corporation (DERM) ranks #810 by composite RQD confidence (31/100, grade E) and #606 by equity capitalization ($152.7M). Within this direct 5-issuer industry benchmark cohort, DERM leads on earnings valuation at N/A trailing P/E, while DERM leads on capital efficiency and profitability with -19.5% ROIC and 65.8% gross margin. ALXO currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with DERM at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| DERM
ACTIVE
Journey Medical Corporation | E | 31/100 | — | 65.8% | -19.5% | -4.44% | $152.7M | Benchmark Subject |
| ALXO ALX Oncology Holdings Inc. | D | 50/100 | — | — | -35.0% | 0.00% | $152.4M | /alxo-vs-derm → |
| MGNX MacroGenics Inc. | E | 31/100 | — | 96.0% | -35.0% | +0.84% | $151.6M | /mgnx-vs-derm → |
| NGEN NervGen Pharma Corp. | D | 49/100 | — | — | — | -4.86% | $155.0M | /ngen-vs-derm → |
| CUE Cue Biopharma Inc. | E | 33/100 | — | — | -35.0% | -2.70% | $155.8M | /cue-vs-derm → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001867066In its most recent audited fiscal period (FY2025, filed 2025-12-31), Journey Medical Corporation (DERM) reported GAAP revenue of $61.2M (+11.1% vs. FY2024 revenue of $55.1M , and +2.6% cumulative change since FY2023) , GAAP net income of -$11.4M, operating cash flow of -$12.4M, and free cash flow of -$12.4M (-36.3% YoY). On the balance sheet, DERM closed FY2025 with $94.6M in total assets against $25.3M in total debt (Altman Z-Score: 0.74, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $61.2M | -$11.4M | -$12.4M | -$12.4M | $94.6M | $25.3M |
| FY2024 (FY) | 2024-12-31 | $55.1M | -$14.7M | -$9.1M | -$9.1M | $80.2M | $24.9M |
| FY2023 (FY) | 2023-12-31 | $59.7M | -$3.9M | $5.2M | $5.2M | — | — |
3. DERM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs DERM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Journey Medical Corporation (NASDAQ: DERM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $5.17 (-4.44% 1D, market cap $152.7M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DERM ranks #810 in composite RQD confidence.
How does DERM compare to ALXO and MGNX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DERM carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 65.8%, and ROIC of -19.5%. By comparison, ALXO (ALX Oncology Holdings Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $152.4M) and MGNX (MacroGenics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $151.6M). Among the 5-stock peer group, DERM leads on earnings multiple (N/A) while DERM leads on capital efficiency (-19.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for DERM?
Per DERM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001867066), Journey Medical Corporation generated $61.2M in revenue (+11.1% YoY), -$11.4M in net income, and -$12.4M in free cash flow against $94.6M in total assets and $25.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is DERM trading relative to its 50-day, 200-day, and 52-week technical levels?
DERM last traded at $5.17 (-4.44% on volume of 235,062 shares), positioning the stock -20.71% below its 50-day simple moving average ($6.52) and -22.14% below its 200-day simple moving average ($6.64). Across its 52-week range of $4.31 to $9.56, DERM sits at the 16.4% percentile with a 14-day RSI of 40.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.52 to $5.82).
DERM Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is DERM stock moving today?
Why DERM Stock dropped -4.44% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-20% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 31/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
DERM — Journey Medical Corporation: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:42:31Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, DERM scores 31 out of 100 for a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 1/20 (ROIC -19.5%; FCF yield -8.15%), Whale 13F Flow at 12/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 10/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 5/20 (Altman Z 0.74; Piotroski F 5/9; Debt/Equity 0.79).
The weakest pillars are the cash engine and insider conviction, which together indicate that the reported economics are not currently producing free cash flow and that insider-flow signals provide little support. The forensic balance-sheet pillar also scores low, with an Altman Z of 0.74 falling in a range the rating treats as distress-adjacent. The whale-flow pillar is the strongest contributor, suggesting that institutional positioning is more constructive than the fundamentals alone would imply. For a prospective investor, the upside case rests mainly on a possible reversal in cash generation or on continued institutional accumulation; the valuation tradeoff is that a low-cap, negative-ROIC profile carries materially higher downside sensitivity to any further operating deterioration.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $61.2M | $-8.2M | $-11.4M | N/A | $-12.4M | $24.1M | $25.3M |
| FY 2024 | $55.1M | $-13.7M | $-14.7M | N/A | $-9.1M | $20.3M | $24.9M |
| FY 2023 | $59.7M | $-2.1M | $-3.9M | N/A | $5.2M | N/A | N/A |
Per the market data section, gross margin is 65.8%, operating margin is -13.3%, and net margin is -18.7%, with ROIC at -19.5%. Per the Roarable RQD rating, the Altman Z-Score is 0.74 and the Piotroski F-Score is 5/9, with Debt/Equity at 0.79. Reported operating and net losses appear in both FY 2025 and FY 2024, while FY 2023 shows a small positive free cash flow of $5.2M. Cash rose from $20.3M to $24.1M across FY 2024 to FY 2025 while debt was broadly stable at $24.9M to $25.3M.
Recent Catalysts & News Wire Analysis
- Market wire (TradingView, 1h ago): A DERM estimates report; no content beyond the headline is provided. Light: YELLOW.
- Market wire (Stock Titan, 3h ago): Reports that an investment adviser disclosed passive ownership of 2.45M shares. Light: YELLOW.
- Market wire (MarketBeat, 6h ago): Reports a move down to "Hold" by Wall Street Zen. Light: YELLOW.
- Catalyst (Yahoo Finance, 9h ago): A headline about Korro Bio, Inc. (KRRO) surging 29.7%; this is a different issuer and is not a direct DERM catalyst. Light: GREEN.
- Catalyst (9h–12h window, source listed as siam.in): A headline reporting DERM up 6.04% as shares reclaim ground toward $5.09 per the fair value gap framing. Light: GREEN.
- Market wire (MarketBeat, 15h ago): Reports a Buy rating reiterated at HC Wainwright. Light: YELLOW.
Risk watch items: the Wall Street Zen downgrade to "Hold" and the price decline of -4.44% reflected in market data. Proprietary signals: none. Butterfly supply-chain graph: supply chain NONE, butterfly links none.
Open Questions
- What specific products and revenue sources generate the $61.2M of FY 2025 revenue, and how concentrated are they?
- What is the path to positive operating and free cash flow given the reported losses in FY 2024 and FY 2025?
- What is the reason for the FY 2023 cash and debt figures being unavailable, and how do they compare to later periods?
- What is the company's EPS and valuation multiple profile, given that P/E and EV/EBITDA are unavailable?
- Does the 2.45M-share passive ownership disclosure reflect a material change in institutional positioning?
DERM Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Journey Medical Corporation (DERM) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 6h ago
Journey Medical Corporation Estimates – NASDAQ:DERM TradingView report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 9h ago
An investment adviser reports passive ownership of 2.45M shares in Journey Medical (DERM). Stock Titan report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 12h ago
Journey Medical (NASDAQ:DERM) Stock Moved Down to "Hold" by Wall Street Zen MarketBeat report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 15h ago
Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains? Yahoo Finance report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST https://www.siam.in/ • 18h ago
Journey Medical Corporation (DERM) Jumps 6.04% as Shares Reclaim Ground Toward $5.09 - Fair Value Gap https://www.siam.in/ report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 21h ago
Journey Medical's (DERM) Buy Rating Reiterated at HC Wainwright MarketBeat report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Medexus Pharmaceuticals Inc. (MDP.TO) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
Journey Medical Q3 2026 Earnings Date and Estimates MarketBeat report covering Journey Medical Corporation (DERM) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
DERM Bull vs. Bear Conversation Board — What's Your Call at $5.17?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DERM 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $4.55 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is DERM (E • RQD 31/100) a Buy at $5.17?
Welcome to the DERM (Journey Medical Corporation) Roar Pit. Current RQD Composite is 31/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $4.29 (-17.0%)
Spot @ $5.17 Pump the brakes on DERM — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on DERM, but look at what you are paying: current EV/EBITDA multiples with 65.8% gross margins. Unless Journey Medical Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH
🎯 Target: $6.20 (+19.9%)
Spot @ $5.17 DERM cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on DERM, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $5.17 (52-wk range $4.31 - $9.56), any beat on forward guidance forces shorts and underweight funds to chase.